Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
November 2, 2017
Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7
SAN DIEGO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it will host a live R&D ...
November 2, 2017
Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), today announced operating and financial results for the third quarter ended ...
November 2, 2017
AIT Therapeutics Completes Treatment of Patient Infected with NTM abscessus at the National Institute of Health (NIH) with its Nitric Oxide (NO) Treatment
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the ...
November 2, 2017
UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors
RA’ANANA, Israel and NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs ...
November 2, 2017
BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 2, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
November 1, 2017
BIOPHYTIS Completes a €7.5 M Capital Increase to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases
PARIS, Nov. 01, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company focused on innovative therapeutics to restore the muscular and visual functions ...
November 1, 2017
Galmed Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 9th
TEL AVIV, Israel, Nov. 1, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for ...
November 1, 2017
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation
LAVAL, QC, Nov. 1, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that it has received Swedish Medical Products Agency (MPA) Clinical ...
November 1, 2017
Intec Pharma, Ltd. Announces Changes to its Board of Directors
JERUSALEM, November 1, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion ...
November 1, 2017
CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia
MONMOUTH JUNCTION, N.J., Nov. 1, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using blood purification to treat life-threatening injury and infection in ...
November 1, 2017
iCAD to Report Third Quarter 2017 Financial Results on Wednesday, November 8
NASHUA, N.H., Nov. 01, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the ...
November 1, 2017
Aimmune Therapeutics to Participate in Four Investor Conferences in November
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team ...
November 1, 2017
Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program
PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, has received approval for a $4.8 million ...
November 1, 2017
Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients
REHOVOT, Israel, Nov. 01, 2017 (GLOBE NEWSWIRE) --  Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced top-line results ...
November 1, 2017
CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8
NEWARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
November 1, 2017
AIT Therapeutics Enters Letter of Intent to License Revolutionary Nitric Oxide (NO) Delivery System and Adds Two Key Executives with Unparalleled Achievements in Developing NO Delivery Systems
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the ...
November 1, 2017
Rockwell Medical Schedules Third Quarter 2017 Earnings Call
WIXOM, Mich., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease ...
November 1, 2017
ASPiRA Labs Announces a Major Coverage Milestone - A 27% Increase in Covered Lives for OVA1
AUSTIN, Texas, Nov. 1, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), today announced ...
November 1, 2017
Catalyst Biosciences Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at American Society for Hematology
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
November 1, 2017
Kitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package
TEL AVIV, Israel, Nov. 1, 2017 /PRNewswire/ -- Kitov Pharmaceuticals (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that it has received the ...
Page 122 of 158